Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eszopiclone · 1 trial · 2 indications
Mean daily average of CPAP use over 3 months
Executive function is assessed using the validated NIH Toolbox Cognition Battery's Flanker inhibitory control and attention test. In a Flanker task, participants are required to indicate the left-right orientation of a centrally presented stimulus while inhibiting attention to the potentially incongruent stimuli that surround it (i.e., the flankers, typically two on either side). Primary outcome is the overall percent of correct responses in incongruent trials.
| Arm | Type | Description |
|---|---|---|
| Eszopiclone | EXPERIMENTAL | Participants will receive eszopiclone the night of the laboratory split-night polysomnography (PSG, sleep monitoring with and without CPAP therapy). Following polysomnography, participants continue with eszopiclone and CPAP therapy |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo the night of the laboratory split-night polysomnography (PSG, sleep monitoring with and without CPAP therapy). Following polysomnography, participants continue with placebo and CPAP therapy |
| Name | Type | Description |
|---|---|---|
| Eszopiclone | DRUG | 3mg for \< 65 and 2mg for ≥ 65 years |
| Placebo | DRUG | Matched placebo |
Inclusion Criteria: * Able to provide informed consent. * Clinically confirmed new diagnosis of OSA: 1. Polysomnography AHI ≥ 10 per hour of sleep and/or 2. Home sleep apnea testing, respiratory even index, REI ≥ 10 per hour of recording Exclusion Criteria: * Known non-OSA related conditions...
Eszopiclone is a small molecule being studied for use in Sleep Apnea, specifically in the context of Obstructive Sleep Apnea. It is currently in Phase 3 clinical development as an investigational therapy. The drug is being evaluated in a randomized, double-blind, placebo-controlled trial to assess its effects in patients with this condition.
Eszopiclone is a small molecule being developed for Sleep Apnea. Its specific molecular target has not been disclosed in the available information. The drug is currently in Phase 3 clinical trials to evaluate its efficacy and safety in patients with Obstructive Sleep Apnea.
Eszopiclone is being developed by ResMed Inc., a company traded on the New York Stock Exchange under the ticker RMD. ResMed is conducting a Phase 3 clinical trial of Eszopiclone for the treatment of Sleep Apnea and Obstructive Sleep Apnea.
Eszopiclone is in Phase 3 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 3 trial is recruiting participants and is designed to evaluate the drug's effects in patients with Obstructive Sleep Apnea.
Eszopiclone is being studied in a Phase 3 clinical trial registered as NCT07332442, titled "Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea." The trial is recruiting 250 participants in the United States and is randomized, double-blind, and placebo-controlled.
Eszopiclone is the drug name used in the current clinical development program by ResMed Inc. No alternative names for this drug have been disclosed in the available information. It is being investigated specifically for its potential role in treating Sleep Apnea and Obstructive Sleep Apnea.